research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Sweet tea, with sugar added (usually while the tea is still hot from brewing), the mixture then being cooled with ice, is ubiquitous in the Southeastern United States. In these states, when "tea" is mentioned, it usually refers to sweetened iced tea. The unsweetened variant is often called "unsweet" tea instead of unsweetened or plain. The consumption of sweet tea with many meals leads to it sometimes called the "table wine of the South", and this trait is considered an important marker of the culture of the Southern United States. Southern sweet tea is made by brewing tea at double strength, adding a large amount of sugar to the freshly brewed hot tea, and diluting to the proper strength. It is served over a glass full of ice cubes and is often garnished with a slice of lemon. While high fructose corn syrup is commonly used as a sweetener for commercially manufactured tea, more often consumers are unaware of this, and when made at home, refined sugar is used. Other forms of iced sweet tea popular in the United States include iced tea with lemonade (commonly called an Arnold Palmer), iced tea lattes (with cow's milk or plant based milk), Bubble tea, and iced tea with some fruit flavoring. Some venues serve iced tea that has been pre-flavored with fruit essences, like passion fruit or peach. Iced tea is often prepared from bagged tea. In addition to tea bags and loose tea, powdered "instant iced tea mix" is available in stores. This is made by preparing tea and then dehydrating it, similar to instant coffee.
== Education and career == Nguyen received an undergraduate degree in chemistry from Imperial College London, followed by a master's degree in health policy, planning and finance London School of Economics and from the London School of Hygiene and Tropical Medicine (LSHTM). She worked for the World Health Organization where she conducted research on medical policies. Between 1999 and 2010, she worked at GlaxoSmithKline and led the development of policies on access to medications and vaccines in the developing world. She joined Gavi in 2011, where she worked find ways to support financially sustainable vaccine programs and markets, and notably worked on strategies to supply Ebola vaccines and HPV vaccines against cervical cancer to developing countries. In October 2020, she was appointed managing director of the Office of the COVAX Facility. In 2021, Nguyen was selected as a Bloomberg New Economy Catalyst. As part of the program, Aurelia attended the annual New Economy Forum held in Singapore, and the Bloomberg New Economy Catalyst Retreat that same year.
On receiving a zero blood ADH signal, the kidneys produce stable albeit larger volumes of very dilute urine, causing dehydration and death if left untreated. As organisms age, the efficiency of their control systems decays. The inefficiencies gradually result in an unstable internal environment that increases the risk of illness, and leads to the physical changes associated with aging. Various chronic diseases are kept under control by homeostatic compensation, which masks a problem by compensating for it (making up for it) in another way. However, the compensating mechanisms eventually wear out or are disrupted by a new complicating factor (such as the advent of a concurrent acute viral infection), which sends the body reeling through a new cascade of events. Such decompensation unmasks the underlying disease, worsening its symptoms. Common examples include decompensated heart failure, kidney failure, and liver failure according to Fan et al. (2011).
== Pathophysiology == The pathophysiology of unstable angina is controversial. Previously, unstable angina was assumed to be angina pectoris caused by disruption of an atherosclerotic plaque with partial thrombosis and possibly embolization or vasospasm leading to myocardial ischemia. However, sensitive troponin assays reveal rise of cardiac troponin in the bloodstream with episodes of even mild myocardial ischemia. Since unstable angina is assumed to occur in the setting of acute myocardial ischemia without troponin release, the concept of unstable angina is being questioned with some calling for retiring the term altogether.
=== Areolar tissue === Areolar tissue ( or ) is a common type of loose connective tissue (and the most widely distributed type of connective tissue in vertebrates). It is so-named because its fibers are far enough apart to leave ample open space for interstitial fluid in between (areola is Latin for a "little open space"). It is strong enough to bind different tissue types together, yet soft enough to provide flexibility and cushioning. It exhibits interlacing, loosely organized fibers, abundant blood vessels, and significant empty space filled with interstitial fluid. Many adjacent epithelial tissues (which are avascular) get their nutrients from the interstitial fluid of areolar tissue; the lamina propria is areolar in many body locations. Its fibers run in random directions and are mostly collagenous, but elastic and reticular fibers are also present. Areolar tissue is highly variable in appearance. In many serous membranes, it appears as a loose arrangement of collagenous and elastic fibers, scattered cells of various types; abundant ground substance; numerous blood vessels. In the skin and mucous membranes, it is more compact and sometimes difficult to distinguish from dense irregular connective tissue.
Sources: en.wikipedia.org
side chain A chemical substituent group that is attached to the core part or "backbone" of a larger molecule, especially an oligomeric or polymeric hydrocarbon chain that branches off of the longer primary chain of a macromolecule. The term is most commonly encountered in biochemistry and organic chemistry.
State defense forces (SDFs) are military units that operate under the sole authority of a state government. SDFs are authorized by state and federal law but are under the command of the state's governor. By contrast, the 54 U.S. National Guard organizations fall under the dual control of state or territorial governments and the federal government; their units can also become federalized entities, but SDFs cannot be federalized. The National Guard personnel of a state or territory can be federalized by the president under the National Defense Act Amendments of 1933; this legislation created the Guard and provides for the integration of Army National Guard and Air National Guard units and personnel into the U.S. Army and (since 1947) the U.S. Air Force. The total number of National Guard members is about 430,000, while the estimated combined strength of SDFs is less than 10,000.
=== Severe combined immunodeficiency === Severe combined immunodeficiency (SCID) caused by T-cell deficiency is a disorder that was recently added to newborn screening programs in some regions of the United States. Wisconsin was the first state to add SCID to their mandatory screening panel in 2008, and it was recommended for inclusion in all states' panels in 2010. Since December 2018 all US states perform SCID screening. As the first country in Europe, Norway started nationwide SCID screening January 2018. Identification of infants with SCID is done by detecting T-cell receptor excision circles (TRECs) using real-time polymerase chain reaction (qPCR). TRECs are decreased in infants affected with SCID. SCID has not been added to newborn screening in a wide scale for several reasons. It requires technology that is not currently used in most newborn screening labs, as PCR is not used for any other assays included in screening programs. Follow-up and treatment of affected infants also requires skilled immunologists, which may not be available in all regions. Treatment for SCID is a stem cell transplant, which cannot be done in all centers.
Upon returning from questioning by the FBI, Eddie and Lily realize that they are being framed after encountering planted evidence in both of their houses. The two flee to an observatory in Wisconsin belonging to Maggie McDermott, an old friend of Eddie's. After resting up, they contact Paul but are almost caught and narrowly escape. As the pair are evading more police, Paul meets with Lyman Earl Collier at the C-Systems Research complex, where it is revealed that C-Systems orchestrated the plot to destroy the laboratory and frame the pair for it, with Lyman ordering the attack. Despite some disagreement, Paul and Lyman decide to continue hunting for the pair, a task facilitated when Eddie covertly arranges a meeting with Paul. At their rendezvous, Paul reveals his involvement in framing Eddie, but the meeting ends in an ambush in which Lyman's thugs Yusef Reed and Clancy Butler, who murdered Alistair, capture Lily while Eddie barely escapes. After tracing the license plate on the thugs' van, Eddie tracks them to the secret C-Systems Research facility where Paul and Lyman are forcing Lily and Chen to replicate the project. When C-Systems' test reactor malfunctions, Paul, the scientists and the prisoners all depart, allowing Eddie to furtively "fix" the system that night. The next morning, one of the other scientists discovers the working reactor and everyone celebrates. A suspicious Paul immediately obtains a download of the fusion data, and secretly gives it to his assistant, Anita, for safekeeping.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.